News | Blood Testing | November 18, 2015

Konica Minolta Starting In Vitro Diagnostics Business in European, American Markets

Company’s SPFS Immunoassay System on reference exhibit at MEDICA 2015 in Germany

November 18, 2015 — Konica Minolta Inc. announced that it has developed the SPFS Immunoassay System, capable of highly sensitive measurements based on the fluorescent antibody technique. A prototype will be on reference exhibit at MEDICA 2015, the world’s largest international medical equipment fair in Dusseldorf, Germany, Nov. 16-19, 2015.

As a diagnostic method for myocardial infarction, malignancies and other pathologic conditions, the fluorescent antibody technique is used to detect disease-associated biomarkers (proteins) in the blood by means of the light generated with the use of a labeled antibody (an antibody coupled with a chemical substance known as a fluorescent marker). Recognizing that its technologies could be useful for increasing the sensitivity of the fluorescent antibody technique, Konica Minolta has been developing the SPFS Immunoassay System.

Specifically, the company’s nanotechnology and fine chemical technology that have emerged and evolved from the development of photographic films make chemical reactions highly controllable, and allow target antibodies to be detected with high sensitivity at the molecular level. In addition, the lens design know-how and light-guiding technology honed through the development of cameras are expected to be particularly useful in the detection of weak light and fluorescence, as well as other situations, thus improving the performance of such tests.

Among acute myocardial infarction patients who are admitted to hospital for emergency treatment for chest pain, those with non-ST elevation acute coronary syndromes are expected to enjoy shorter recovery times after treatment and lower mortality rates by starting early diagnosis and treatment with the use of highly sensitive testing. However, the conventional test with troponin (a biomarker (protein) in heart muscle), which is currently used for diagnosing myocardial infarction, requires about 6 hours for diagnosis, and is reported to have accuracy problems, causing various major issues in emergency medicine, including overcrowding.

Konica Minolta has developed the SPFS Immunoassay System, which comprises a compact unit for highly sensitive measurement of troponin with a diagnosis time of just 3 hours, and a set of heart disease-related reagents, including troponin. The system will be able to dramatically increase the efficiency of diagnostic and other clinical activities, and lessen overcrowding in emergency care settings, thus helping to reduce patient mortality rates and facilitate early recovery and discharge.

Furthermore, the SPFS Immunoassay System can accurately detect disease-specific biomarkers (proteins found specifically in target diseases) to provide a highly reliable immunoassay system not only for heart diseases such as myocardial infarction, but also for malignancies and other diseases, thus improving medical care.

Konica Minolta is planning to launch the SPFS Immunoassay System incorporating markers related to heart diseases primarily in Europe in 2017, and then sell it in both the European and American markets.
The company is also planning to create a more efficient immunoassay system with a greater number of test parameters, and to fully enter the in vitro diagnostics market with the high-sensitivity immunoassay system.

For more information:

Related Content

More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init